Brief: Biohaven Announces FDA Acceptance And Priority Review Of Troriluzole New Drug Application
11/02/2025 13:02
Feb 11 (Reuters) - Biohaven BHVN.N :
* BIOHAVEN ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF
TRORILUZOLE NEW DRUG APPLICATION FOR THE TREATMENT OF
SPINOCEREBELLAR ATAXIA
* BIOHAVEN LTD - FDA DECISION ON TRORILUZOLE NDA EXPECTED BY
3Q2025
* BIOHAVEN LTD - PREPARED TO COMMERCIALIZE TRORILUZOLE FOR
SCA IN
2025
Source text: ID:nPnsctV5a
Further company coverage: BHVN.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biohaven
See all newsActing US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing